Efficacy of ACE‐inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Endocrinology

• Publication date

  2005-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2265.2005.02292.xPMID 15963056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Literature abstracts

  2005cited by this paper
• Role of Endothelium-Derived Hyperpolarizing Factor in ACE Inhibitor-Induced Renal Vasodilation in Vivo

  2004cited by this paper
• Type I glycogen storage disease: Kidney involvement, pathogenesis and its treatment

  2004cited by this paper
• Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

  2003cited by this paper
• Regression of microalbuminuria in type 1 diabetes.

  2003cited by this paper
• Ramipril treatment in a patient with glycogen storage disease I non-A

  2002cited by this paper
• Glycogenosis type I and diabetes mellitus: a common mechanism for renal dysfunction?

  2002cited by this paper
• Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I)

  2002cited by this paper
• Effect of ramipril in a patient with glycogen storage disease type I and nephrotic-range proteinuria

  2001cited by this paper
• Short-term effect of captopril on microalbuminuria in children with glycogen storage disease type Ia

  2000cited by this paper
• Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria

  1999cited by this paper
• Mutations in the glucose‐6‐phosphate transporter (G6PT) gene in patients with glycogen storage diseases type 1b and 1c

  1999cited by this paper
• Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

  1998cited by this paper
• Structure and mutation analysis of the glycogen storage disease type 1b gene

  1998cited by this paper
• Metabolic control and renal dysfunction in type I glycogen storage disease

  1997cited by this paper
• Focal segmental glomerulosclerosis

  1996cited by this paper
• Mutations in the glucose-6-phosphatase gene are associated with glycogen storage disease types 1a and 1aSP but not 1b and 1c.

  1995cited by this paper
• Glomerular and tubular function in glycogen storage disease

  1995cited by this paper
• Hyperfiltration and renal disease in glycogen storage disease, type I.

  1989cited by this paper
• The Effect of Exocrine Pancreatic Function on Chloramphenicol Pharmacokinetics in Patients with Cystic Fibrosis

  1988cited by this paper
• Renal disease in type I glycogen storage disease.

  1988cited by this paper
• The Dietary Treatment of Children with Type I Glycogen Storage Disease with Slow Release Carbohydrate

  1984cited by this paper
• Lactate as a Cerebral Metabolic Fuel for Glucose-6-Phosphatase Deficient Children

  1984cited by this paper
• Nocturnal Gastric Drip Feeding in Glucose-6-Phosphatase Deficient Children

  1979cited by this paper
• Developmental Nephrology

  1974cited by this paper
• Glycogen storage disease.

  1948cited by this paper

• The kidney in genetic metabolic disorders

  2026cites this paper
• Kidney involvement in glycogen storage disease type I: Current knowledge and key challenges.

  2025cites this paper
• Endocrine Complications in Hepatic Glycogen Storage Diseases: A Long-term Perspective

  2024cites this paper
• Glycogen storage diseases: An update

  2023cites this paper
• Glycogen storage disease type I: Genetic etiology, clinical manifestations, and conventional and gene therapies

  2023cites this paper
• Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia.

  2023cites this paper
• Clinical, Biochemical and Molecular Characterization of a Cohort of Glycogen Storage Disease Type I Patients in a High Complexity Hospital in Argentina

  2021cites this paper
• Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy

  2021influential citation
• Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients

  2021cites this paper
• Hypoglycemia in the Newborn and Infant

  2021cites this paper
• Kidney and Metabolic Phenotypes in Glycogen Storage Disease Type-I Patients

  2020cites this paper
• Glycogénoses

  2018cites this paper
• Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control

  2017cites this paper
• Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy

  2017cites this paper
• Progressive development of renal cysts in glycogen storage disease type I.

  2016cites this paper
• A systematic review of glomerular hyperfiltration assessment and definition in the medical literature.

  2015cites this paper
• Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation

  2015cites this paper
• Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study.

  2015cites this paper
• [Renal involvement in glycogen storage disease type 1: Practical issues].

  2015cites this paper
• Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.

  2014cites this paper
• Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

  2014cites this paper
• Multiple roles of glucose-6-phosphatases in pathophysiology: state of the art and future trends.

  2013cites this paper
• Current status of hepatic glycogen storage disease in Japan: clinical manifestations, treatments and long-term outcomes

  2013cites this paper
• Glycogen storage disease type 1 and diabetes: learning by comparing and contrasting the two disorders.

  2013cites this paper
• Glycogen Storage Disease type 1a – a secondary cause for hyperlipidemia: report of five cases

  2013cites this paper
• Glycogen storage disease type I (GSD I)

  2012cites this paper
• INHIBITION OF RENNIN(cid:26)ANGIOTENSIN(cid:26)ALDOSTERONE SYSTEM AND NEPHROPROTECTION

  2012cites this paper
• Glucose-6-phosphatase deficiency

  2011cites this paper
• Oxidative stress mediates nephropathy in type Ia glycogen storage disease

  2010cites this paper
• Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy

  2010cites this paper
• Early diagnosis and treatment may prevent the development of complications in an adult patient with glycogen storage disease type Ia.

  2010cites this paper
• Early Diagnosis and Treatment may Prevent the Development of Complications in an Adult Patient with Glycogen Storage Disease Type Ιa

  2010cites this paper
• Renal Manifestations of Metabolic Disorders

  2009cites this paper
• Liver transplantation for glycogen storage disease type Ia.

  2009cites this paper
• Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

  2009cites this paper
• Emerging therapies for glycogen storage disease type I.

  2009cites this paper
• Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.

  2008cites this paper
• Nutritional Therapy for Glycogen Storage Diseases

  2008cites this paper
• a u p o in t Histoire naturelle des glycogénoses avec atteinte hépatique

  2008influential citation
• [Natural history of hepatic glycogen storage diseases].

  2008cites this paper
• CHAPTER 5 – Hypoglycemia in Neonates and Infants

  2008cites this paper
• Role of ACE inhibitors in patients with glycogen storage disease type 1

  2005cites this paper
• Index

  2005cites this paper